Users Online: 379

Home Print this page Email this page Small font sizeDefault font sizeIncrease font size

Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 
     
REVIEW ARTICLE
Year : 2022  |  Volume : 12  |  Issue : 3  |  Page : 99-104

The Risk of COVID-19 in Patients of Chronic Kidney Disease with Cognitive Dysfunction Like Alzheimer Disease: A Perspective on Erythropoietin as a Potential Adjuvant Therapy


1 Department of Medical Research, Dr V Balaji Dr V Seshiah Diabetes Care and Research Institute, Aminjikarai, Chennai, Tamil Nadu; Department of Medical Research, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India
2 Department of Medical Research, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Chennai, Tamil Nadu, India
3 Department of Mathematics, Sathyabama institute of science and technology, Chennai, Tamil Nadu, India

Correspondence Address:
PhD Venkataraman Prabhu
Associate Professor, Department of Medical Research, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur – 603203
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijnpnd.ijnpnd_35_22

Rights and Permissions

Background: The universal risk to mankind, coronavirus disease 2019 (COVID-19), shares etiological cofactors with a variety of diseases, including anemic chronic kidney disease patients (CKD) with cognitive dysfunction like Alzheimer disease (AD). Understanding the shared links between COVID-19 and CKD, as well as cognitive impairment such as AD, might aid in designing therapeutic ways to combat both. Given the need of developing COVID-19 medicine, the connection and symptoms of CKD with cognitive impairment have been reviewed here, with a focus on memory and learning disturbance. Objective: COVID-19 and CKD with cognitive dysfunction share angiotensin-converting enzyme 2 receptors, and AD indicators include amyloid, tau protein, and glycogen synthase kinase-3β. Anemia in patients with CKD and pulmonary fibrosis is frequently treated with recombinant human erythropoietin (rHuEPO). Through nitric oxide stimulation, neuroprotection, and various organ hypoxias, rHuEPO promotes red blood cells (RBC) growth while also assisting oxygen delivery. Results and Conclusions: In COVID-19, rHuEPO may be advantageous. The common etiological variables and manifestations outlined in this review could aid in the development of therapeutic options for COVID-19 and CKD with cognitive impairment, such as AD, and so help to eliminate the ongoing universal risk.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed626    
    Printed36    
    Emailed0    
    PDF Downloaded98    
    Comments [Add]    

Recommend this journal